These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 7940974)

  • 1. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.
    Zamora MR; Fullerton DA; Campbell DN; Leone S; Diercks MJ; Fisher JH; Badesch DB; Grover FL
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):49-51. PubMed ID: 7940974
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of intravenous ganciclovir and cytomegalovirus hyperimmune globulin pre-emptive treatment in cytomegalovirus-positive heart transplant recipients.
    Vrtovec B; Thomas CD; Radovancevic R; Frazier OH; Radovancevic B
    J Heart Lung Transplant; 2004 Apr; 23(4):461-5. PubMed ID: 15063406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined CMV prophylaxis improves outcome and reduces the risk for bronchiolitis obliterans syndrome (BOS) after lung transplantation.
    Ruttmann E; Geltner C; Bucher B; Ulmer H; Höfer D; Hangler HB; Semsroth S; Margreiter R; Laufer G; Müller LC
    Transplantation; 2006 May; 81(10):1415-20. PubMed ID: 16732179
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CMV-hyperimmune globulin for preventing cytomegalovirus infection and disease in solid organ transplant recipients: a meta-analysis.
    Bonaros N; Mayer B; Schachner T; Laufer G; Kocher A
    Clin Transplant; 2008; 22(1):89-97. PubMed ID: 18217909
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Delay of CMV infection in high-risk CMV mismatch lung transplant recipients due to prophylaxis with oral ganciclovir.
    Palmer SM; Grinnan DC; Diane Reams B; Steele MP; Messier RH; Duane Davis R
    Clin Transplant; 2004 Apr; 18(2):179-85. PubMed ID: 15016133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Boston Center for Liver Transplantation CMVIG-Study Group.
    Snydman DR; Werner BG; Dougherty NN; Griffith J; Rohrer RH; Freeman R; Jenkins R; Lewis WD; O'Rourke E
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):23-7. PubMed ID: 7940972
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group.
    Falagas ME; Snydman DR; Ruthazer R; Griffith J; Werner BG; Freeman R; Rohrer R
    Clin Transplant; 1997 Oct; 11(5 Pt 1):432-7. PubMed ID: 9361936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized clinical trial of ganciclovir vs acyclovir for prevention of cytomegalovirus antigenemia after allogeneic transplantation.
    Burns LJ; Miller W; Kandaswamy C; DeFor TE; MacMillan ML; Van Burik JA; Weisdorf DJ
    Bone Marrow Transplant; 2002 Dec; 30(12):945-51. PubMed ID: 12476289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of cytomegalovirus hyperimmune globulin on outcome after cardiothoracic transplantation: a comparative study of combined prophylaxis with CMV hyperimmune globulin plus ganciclovir versus ganciclovir alone.
    Valantine HA; Luikart H; Doyle R; Theodore J; Hunt S; Oyer P; Robbins R; Berry G; Reitz B
    Transplantation; 2001 Nov; 72(10):1647-52. PubMed ID: 11726825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should heart-lung transplant donors and recipients be matched according to cytomegalovirus serologic status?
    Novick RJ; Menkis AH; McKenzie FN; Reid KR; Ahmad D
    J Heart Transplant; 1990; 9(6):699-706. PubMed ID: 2177496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients.
    Soghikian MV; Valentine VG; Berry GJ; Patel HR; Robbins RC; Theodore J
    J Heart Lung Transplant; 1996 Sep; 15(9):881-7. PubMed ID: 8889983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized controlled trial of oral ganciclovir versus oral acyclovir after induction with intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in cytomegalovirus-seropositive liver transplant recipients.
    Winston DJ; Busuttil RW
    Transplantation; 2003 Jan; 75(2):229-33. PubMed ID: 12548129
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis.
    Rubin RH; Kemmerly SA; Conti D; Doran M; Murray BM; Neylan JF; Pappas C; Pitts D; Avery R; Pavlakis M; Del Busto R; DeNofrio D; Blumberg EA; Schoenfeld DA; Donohue T; Fisher SA; Fishman JA
    Transpl Infect Dis; 2000 Sep; 2(3):112-7. PubMed ID: 11429021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment of cytomegalovirus infections in renal transplants].
    Rondeau E; Peraldi MN; Kanfer A; Sraer JD
    Nephrologie; 1991; 12(4):189-92. PubMed ID: 1660570
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elimination of cytomegalovirus disease in liver transplant patients treated prophylactically with combination cytomegalovirus hyperimmune globulin and ganciclovir.
    Prian GW; Koep LJ
    Transplant Proc; 1994 Oct; 26(5 Suppl 1):54-5. PubMed ID: 7940977
    [No Abstract]   [Full Text] [Related]  

  • 17. Efficacy of a 6-week prophylactic ganciclovir regimen and the role of serial cytomegalovirus antibody testing in lung transplant recipients.
    Kelly JL; Albert RK; Wood DE; Raghu G
    Transplantation; 1995 Apr; 59(8):1144-7. PubMed ID: 7732561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cytomegalovirus Immunoglobulin After Thoracic Transplantation: An Overview.
    Grossi P; Mohacsi P; Szabolcs Z; Potena L
    Transplantation; 2016 Mar; 100 Suppl 3(Suppl 3):S1-4. PubMed ID: 26900989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus-seropositive donors.
    Shah T; Lai WK; Mutimer D
    Transpl Infect Dis; 2005 Jun; 7(2):57-62. PubMed ID: 16150091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.